Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

Thinking Big, Thinking Small

Philip Seo, MD, MHS  |  June 17, 2019

I would like to tell you a story. Two, actually. I am just returning from the 19th International Vasculitis and ANCA Workshop, which is always a fascinating meeting. In its inception, it was a workshop, in the true sense of the word. Now, we discuss anti-neutrophil cytoplasmic antibody (ANCA) testing as casually as we discuss…

Filed under:ConditionsVasculitis Tagged with:ANCA-Associated Vasculitisanti-neutrophil cytoplasmic antibodies (ANCA)genomicsInternational Vasculitis and ANCA WorkshopKawasaki disease

Biological DMARDs in Elderly RA Patients: Use, Maintenance & Discontinuation

Natasha Yetman  |  June 17, 2019

A study comparing seven biologic DMARDs in RA patients aged 65 years and older found abatacept had the highest retention rate and the lowest discontinuation rate…

Filed under:ConditionsRheumatoid Arthritis Tagged with:abataceptadalimumabbiologic disease-modifying antirheumatic drugsbiologic DMARDsCertolizumab PegoletanerceptGolimumabinfliximabRheumatoid Arthritis (RA)tocilizumab

The ACR’s & EULAR’s Gout Guidelines Include Treatment Approaches

Mary Beth Nierengarten  |  May 18, 2019

SNOWMASS VILLAGE, COLO.—The 2019 ACR Winter Rheumatology Symposium featured a session on gout. Despite a good understanding of its pathogenesis and the many effective therapies to treat it, gout remains a major public health problem in the U.S. Ann K. Rosenthal, MD, Will and Cava Ross professor of medicine and chief of the Division of…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinollesinuradProbenecidurate-lowering therapies

Chronic Opioid Use in Rheumatoid Arthritis: Prevalence & Predictors

Arthritis & Rheumatology  |  May 1, 2019

Over the past decade, physicians, patients and policy makers have expressed increasing concern about the high frequency of opioids being prescribed and the association between opioid use and poor outcomes. Rates of opioid prescriptions in the general population rose considerably from the 1990s through 2010, with a plateau in the early 2010s. In 2015, 38%…

Filed under:AnalgesicsConditionsDrug UpdatesPain SyndromesResearch Rheum Tagged with:Arthritis & RheumatologyChronic painOpioidsResearchRheumatoid Arthritis (RA)

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD  |  February 17, 2019

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…

Filed under:Biologics/DMARDsResearch RheumRheumatoid ArthritisSpeak Out Rheum Tagged with:OpinionSpeak Out Rheumatology

Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality

Carina Stanton  |  February 14, 2019

At diagnosis, temporal artery biopsy results and large-vessel involvement of patients with giant cell arteritis may be stronger predictors of mortality than cardiovascular risk factors…

Filed under:ConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)mortality

Nonsurgical Therapies for Knee OA Pain: From Medications to Bracing to Exercise, What Works & What Doesn’t

Susan Bernstein  |  November 28, 2018

CHICAGO—Many nonsurgical therapies are available for knee osteoarthritis pain, but they vary greatly in effectiveness. “How should I proceed and figure out what to do with our patients?” asked David T. Felson, MD, MPH, professor of medicine at Boston University School of Medicine, during OA Management Without Surgery in 2018, a session at the 2018…

Filed under:American College of RheumatologyConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:2018 ACR/ARHP Annual Meeting

Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels

Lara C. Pullen, PhD  |  November 26, 2018

An exploratory analysis of a canakinumab clinical trial has shown the interleukin 1β inhibitor may significantly reduce patients’ risk for gout flares. During the study, patients using canakinumab experienced this decreased risk, but the treatment did not change serum uric acid levels…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:anti-interleukincanakinumabflareGout

Pediatric Lupus Outcomes: Researchers Follow Kids into Adulthood

Linda Childers  |  November 19, 2018

A study published in the May issue of Arthritis Care & Research may be the first to examine the long-term outcomes of childhood-onset lupus, otherwise known as pediatric systemic lupus erythematosus (SLE), a chronic, multisystem autoimmune disease with a highly variable clinical course. Previous studies examined cross-sectional views of damage accrued. According to the Childhood…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:FlaresSLICC/ACR Damage Index

Genes, Not Diet, Main Determinant of Urate Levels

Anne Harding  |  October 17, 2018

NEW YORK (Reuters Health)—Heredity plays a substantially larger role than diet in determining serum urate levels, according to new findings in BMJ. Nearly 25% of the variation in serum urate is attributable to common genetic variants, while dietary pattern explained less than 1%, Dr. Tanya J. Major of the University of Otago in Dunedin, New…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Goutheredityserum urate levelsTanya J. Major

  • « Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 64
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences